

Amendments to the Claims:

The following amendments and cancellations to the claims are made without prejudice or disclaimer. This listing of claims replaces all prior versions and listings of claims in the application:

Listing of Claims:

Claims 1-24 (cancelled)

25. (currently amended) A recombinant antibody, or an antigen binding fragment thereof, which specifically binds to the open conformer of  $\alpha$ L integrin relative to another conformer and inhibits interaction of LFA-1 integrin and a cognate LFA-1 integrin ligand a modified integrin I domain in the open conformation.

26. (currently amended) An antibody or an antigen binding fragment thereof, which binds to an activation specific epitope on an integrin I-domain of  $\alpha$ L in the open conformation defined by the E284C-E301C or K287C-K294C mutations, and inhibits interaction of LFA-1 integrin and a cognate LFA-1 integrin ligand.

27 - 29. (cancelled)

30. (currently amended) A recombinant anti-integrin antibody, or an antigen binding fragment thereof, which specifically binds to the open conformer of an  $\alpha$ L integrin I-domain relative to the closed conformer of an  $\alpha$ L integrin I-domain, and inhibits interaction of LFA-1 integrin and a cognate LFA-1 integrin ligand an integrin I domain in the open conformation.

31 - 73 (cancelled)

31 - 73 (cancelled)

74. (currently amended) The antibody or an antigen binding fragment thereof, of claim ~~73~~ 25, wherein ~~said the modified I-domain of an  $\alpha$ L-subunit contains~~ is locked in the open conformation by amino acid substitutions K287C/K294C.

75. (cancelled)

76. (previously presented) The antibody or an antigen binding fragment thereof, of claim 25 or 30, wherein said antibody comprises a portion of a human antibody and a portion of a non-human antibody.

77. (previously presented) The antibody or an antigen binding fragment thereof, of claim 25 or 30, wherein said antibody is a humanized antibody.

78. (previously presented) The antibody or an antigen binding fragment thereof, of claim 25 or 30, wherein said antibody is a chimeric antibody.

79. (currently amended) The antibody or an antigen binding fragment thereof, of claim ~~73~~ 25, wherein ~~said the modified I-domain of an  $\alpha$ L-subunit contains~~ is locked in the open conformation by amino acid substitutions E284C/E301C.

80. (previously presented) The antibody or antigen binding fragment thereof, of claim 25, wherein said antibody, or antigen binding fragment thereof, is identified by screening a phage display library with a modified integrin polypeptide, and isolating said antibody, or antigen binding fragment thereof.

81 – 82. (cancelled)

83. (previously presented) An antibody, or an antigen binding fragment thereof, which binds to an integrin I-domain in the open conformation but not to an integrin I-domain in the closed conformation.

84. (currently amended) An antibody, or an antigen binding fragment thereof, which binds to an integrin I-domain of an  $\alpha$ L integrin, the I-domain being locked in the open conformation by the substitutions E284C-E301C or K287C-K294C mutations but not to a modified integrin I-domain that is locked in the closed conformation by the substitutions K289C/K294C.

85 - 86. (cancelled)

87. (currently amended) The antibody or antigen binding fragment thereof, of claim ~~86~~ 84, wherein the ~~modified integrin~~ I-domain in the open conformation comprises substitutions E284C/E301C in an  $\alpha$ L subunit.

88. (currently amended) The antibody or antigen binding fragment thereof, of claim ~~86~~ 84, wherein the ~~modified integrin~~ I-domain in the open conformation comprises a substitutions K287C/K294C in an  $\alpha$ L subunit.

89 - 104. (cancelled)

105. (previously presented) The antibody or antigen binding fragment, of claim 83 that is a monoclonal antibody.

106. (previously presented) The antibody or antigen binding fragment, of claim 83 that is a recombinant antibody.

107 – 109. (cancelled)

110. (currently amended) The antibody or antigen binding fragment, of claim 25, 26, 30, or 83 that blocks interaction between an integrin and a cognate ligand.

111. (cancelled)

112. (previously presented) The antibody or antigen binding fragment, of claim 110, wherein the cognate ligand is ICAM-1.

113. (previously presented) The antibody or antigen binding fragment, of claim 110, wherein the cognate ligand is ICAM-2 or ICAM-3.

114. (currently amended) The antibody or antigen binding fragment, of claim 25, 26, 30, 83, or 84 ~~75, or 103~~ further comprising a physically linked detectable substance.

115. (previously presented) The antibody or antigen binding fragment, of claim 114, wherein the physically linked detectable substance comprises an enzyme, a fluorescent material, or a radioactive material.

116. (previously presented) The antibody or antigen binding fragment, of claim 114, wherein the physically linked detectable substance comprises a fluorescent or radioactive material.

117. (currently amended) The antibody or antigen binding fragment, of claim 25, 26, 30, or 84 further comprising a therapeutic moiety.

118 - 121. (cancelled)

122. (currently amended) The antibody or antigen binding fragment, of ~~any of claims~~ claim 117 ~~[[121]]~~, wherein the therapeutic moiety comprises a cytotoxin.

123. (currently amended) The antibody or antigen binding fragment, of ~~any of claims~~ claim 117 ~~[[121]]~~, wherein the therapeutic moiety comprises a radioactive metal ion.

124. (currently amended) The antibody or antigen binding fragment, of ~~any of claims~~ claim 117 ~~[[121]]~~, wherein the therapeutic moiety comprises a chemical therapeutic agent.

125. (currently amended) The antibody or antigen binding fragment, of ~~any of claims~~ claim 117 ~~[[121]]~~, wherein the therapeutic moiety comprises a protein possessing a desired biological activity.

126. (currently amended) The antibody or antigen binding fragment, of ~~any of claims~~ claim 117 ~~[[121]]~~, wherein the therapeutic moiety comprises a toxin.

127. (currently amended) A pharmaceutical composition comprising (i) an antibody or antigen binding fragment thereof according to claim 25, ~~26, 27, or 29~~, and (ii) a pharmaceutically acceptable carrier.

128. (currently amended) A pharmaceutical composition comprising (i) an antibody or antigen binding fragment thereof according to claim 30 ~~or 83~~, or 84 and (ii) a pharmaceutically acceptable carrier.

129. (currently amended) A pharmaceutical composition comprising (i) an antibody or antigen binding fragment thereof according to claim [[75]] 26, and (ii) a pharmaceutically acceptable carrier.

130. (cancelled)

131. (new) The antibody or an antigen binding fragment thereof, of claim 25, wherein the open conformer is defined by the E284C-E301C or K287C-K294C mutations.

132. (new) The antibody or an antigen binding fragment thereof, of claim 30, wherein the open conformer is defined by the E284C-E301C or K287C-K294C mutations.

133. (new) A recombinant antibody, or an antigen binding fragment thereof, which binds to an integrin I-domain of an  $\alpha$ L integrin, the I-domain being locked in the open conformation by the substitutions E284C-E301C but not to a modified integrin I-domain that is locked in the closed conformation by the substitutions K289C/K294C, wherein the antibody or antigen binding fragment thereof blocks interaction between LFA-1 and ICAM-1.

134. (new) A recombinant antibody, or an antigen binding fragment thereof, which binds to an integrin I-domain of an  $\alpha$ L integrin, the I-domain being locked in the open conformation by the substitutions K287C-K294C but not to a modified integrin I-domain that is locked in the closed conformation by the substitutions K289C/K294C, wherein the antibody or antigen binding fragment thereof blocks interaction between LFA-1 and ICAM-1.